fluconazole has been researched along with Mucorales Infection in 34 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Fifteen months after the discontinuation of immunosuppressive therapy, Eschericia coli peritonitis developed, which was treated with ceftazidime intraperitoneally; he received fluconazole as prophylactic antifungal therapy during this period." | 7.72 | Successful treatment of mucormycosis peritonitis with liposomal amphotericin B in a patient on long-term peritoneal dialysis. ( Dosekun, AK; Serna, JH; Wanger, A, 2003) |
| "This is a case of mucormycosis complicated by necrotizing fasciitis in a renal transplant recipient on immunosuppressive therapy treated with posaconazole." | 3.74 | Successful treatment and limb salvage of mucor necrotizing fasciitis after kidney transplantation with posaconazole. ( Harada, AS; Lau, W, 2007) |
| " Fifteen months after the discontinuation of immunosuppressive therapy, Eschericia coli peritonitis developed, which was treated with ceftazidime intraperitoneally; he received fluconazole as prophylactic antifungal therapy during this period." | 3.72 | Successful treatment of mucormycosis peritonitis with liposomal amphotericin B in a patient on long-term peritoneal dialysis. ( Dosekun, AK; Serna, JH; Wanger, A, 2003) |
| "Mucormycosis is an aggressive, angioinvasive fungal infection with a predilection for the rhino-orbital cavity, predominantly in immunocompromised patients such as patients with uncontrolled diabetes." | 1.56 | Recognizing mucormycosis in an immunocompromised patient. ( Hunt, E, 2020) |
| "Peritonitis is a common problem in patients undergoing peritoneal dialysis." | 1.38 | Successful treatment of peritonitis by C. bertholletiae in a chronic kidney failure patient on continuous ambulatory peritoneal dialysis after kidney rejection. ( Bhutada, K; Borkar, SS; Mendiratta, DK; Shende, VR, 2012) |
| "Mucormycosis was diagnosed in the neutropenic state following allogeneic hematopoietic cell transplantation (n=3) or intense chemotherapy (n=3)." | 1.33 | Mucormycoses in patients with hematologic malignancies: an emerging fungal infection. ( Bethge, WA; Einsele, H; Hebart, H; Horger, M; Kanz, L; Kröber, SM; Schmalzing, M; Schumacher, U; Stuhler, G, 2005) |
| "The sinusitis was successfully treated with AmBisome, and surgical debridement." | 1.33 | Zygomycosis in the immunocompromised patient: a case report. ( Aoun, M; Beguin, H; Georgala, A; Husson, M; Meuleman, N; Nolard, N; Vekemans, M, 2006) |
| "Rhinocerebral mucormycosis is a rapidly progressive fatal disease." | 1.30 | [A case of rhinocerebral mucormycosis presenting orbital apex syndrome]. ( Suzuka, T; Umemura, A, 1998) |
| "Oral treatment with ketoconazole, itraconazole, fluconazole or saperconazole was inefficacious." | 1.28 | Treatment of experimental zygomycosis in guinea pigs with azoles and with amphotericin B. ( Fransen, J; Janssen, PA; Van Cutsem, J; Van Gerven, F, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.94) | 18.7374 |
| 1990's | 11 (32.35) | 18.2507 |
| 2000's | 13 (38.24) | 29.6817 |
| 2010's | 7 (20.59) | 24.3611 |
| 2020's | 2 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Almyroudis, NG | 1 |
| Sutton, DA | 2 |
| Fothergill, AW | 1 |
| Rinaldi, MG | 1 |
| Kusne, S | 1 |
| Rodríguez, MM | 1 |
| Pastor, FJ | 1 |
| Calvo, E | 1 |
| Salas, V | 1 |
| Guarro, J | 1 |
| Nahide, PD | 1 |
| Alba-Betancourt, C | 1 |
| Chávez-Rivera, R | 1 |
| Romo-Rodríguez, P | 1 |
| Solís-Hernández, M | 1 |
| Segura-Quezada, LA | 1 |
| Torres-Carbajal, KR | 1 |
| Gámez-Montaño, R | 1 |
| Deveze-Álvarez, MA | 1 |
| Ramírez-Morales, MA | 1 |
| Alonso-Castro, AJ | 1 |
| Zapata-Morales, JR | 1 |
| Ruiz-Padilla, AJ | 1 |
| Mendoza-Macías, CL | 1 |
| Meza-Carmen, V | 1 |
| Cortés-García, CJ | 1 |
| Corrales-Escobosa, AR | 1 |
| Núñez-Anita, RE | 1 |
| Ortíz-Alvarado, R | 1 |
| Chacón-García, L | 1 |
| Solorio-Alvarado, CR | 1 |
| Hunt, E | 1 |
| Li, YH | 1 |
| Sun, P | 1 |
| Guo, JC | 1 |
| Macedo, D | 1 |
| Leonardelli, F | 1 |
| Dudiuk, C | 1 |
| Theill, L | 1 |
| Cabeza, MS | 1 |
| Gamarra, S | 1 |
| Garcia-Effron, G | 1 |
| van der Elst, KC | 1 |
| Span, LF | 1 |
| van Hateren, K | 1 |
| Vermeulen, KM | 1 |
| van der Werf, TS | 1 |
| Greijdanus, B | 1 |
| Kosterink, JG | 1 |
| Uges, DR | 1 |
| Alffenaar, JW | 1 |
| Bellanger, AP | 1 |
| Albert, ND | 1 |
| Lewis, RE | 1 |
| Walsh, TJ | 2 |
| Kontoyiannis, DP | 1 |
| Zhou, M | 1 |
| Farooq, AV | 1 |
| Andreoli, MT | 1 |
| Ali, M | 1 |
| Traish, AS | 1 |
| Bamba, S | 1 |
| Konsegré, V | 1 |
| Zida, A | 1 |
| Sangaré, I | 1 |
| Cissé, M | 1 |
| Beogo, R | 1 |
| Diallo, B | 1 |
| Andonaba, JB | 1 |
| Guiguemdé, RT | 1 |
| Shah, S | 1 |
| Suresh, PV | 1 |
| Maheshwari, S | 1 |
| Rao, S | 1 |
| Ramos, A | 1 |
| Cuervas-Mons, V | 1 |
| Noblejas, A | 1 |
| Baños, I | 1 |
| Duran, P | 1 |
| Marcos, R | 1 |
| Sánchez-Turrión, V | 1 |
| Jiménez, M | 1 |
| Arellano, B | 1 |
| Corbacho, C | 1 |
| Sánchez-Romero, I | 1 |
| Bhutada, K | 1 |
| Borkar, SS | 1 |
| Mendiratta, DK | 1 |
| Shende, VR | 1 |
| Serna, JH | 1 |
| Wanger, A | 1 |
| Dosekun, AK | 1 |
| Bethge, WA | 1 |
| Schmalzing, M | 1 |
| Stuhler, G | 1 |
| Schumacher, U | 1 |
| Kröber, SM | 1 |
| Horger, M | 1 |
| Einsele, H | 1 |
| Kanz, L | 1 |
| Hebart, H | 1 |
| Sahin, GO | 1 |
| Akova, M | 1 |
| Yang, G | 1 |
| Lin, J | 1 |
| Dong, X | 1 |
| Wang, H | 1 |
| Liu, X | 1 |
| An, L | 1 |
| Georgala, A | 1 |
| Vekemans, M | 1 |
| Husson, M | 1 |
| Meuleman, N | 1 |
| Beguin, H | 1 |
| Nolard, N | 1 |
| Aoun, M | 1 |
| Harada, AS | 1 |
| Lau, W | 1 |
| Bonifaz, A | 1 |
| Macias, B | 1 |
| Paredes-Farrera, F | 1 |
| Arias, P | 1 |
| Ponce, RM | 1 |
| Araiza, J | 1 |
| Koçak, R | 1 |
| Tetiker, T | 1 |
| Koçak, M | 1 |
| Başlamişli, F | 1 |
| Zorludemir, S | 1 |
| Gönlüşen, G | 1 |
| Woods, SG | 1 |
| Elewski, BE | 1 |
| Carpentier, JP | 1 |
| Petrognani, R | 1 |
| Gonzalez, C | 1 |
| Lyman, CA | 1 |
| Chanock, SJ | 1 |
| Pizzo, PA | 1 |
| Wu, S | 1 |
| Guo, N | 1 |
| Hou, Y | 1 |
| Cáceres, AM | 1 |
| Sardiñas, C | 1 |
| Marcano, C | 1 |
| Guevara, R | 1 |
| Barros, J | 1 |
| Bianchi, G | 1 |
| Rosario, V | 1 |
| Balza, R | 1 |
| Silva, M | 1 |
| Redondo, MC | 1 |
| Nuñez, M | 1 |
| Kauffman, CA | 1 |
| Hedderwick, S | 1 |
| Bouza, E | 1 |
| Burgaleta, C | 1 |
| Umemura, A | 1 |
| Suzuka, T | 1 |
| Sugar, AM | 1 |
| Liu, XP | 1 |
| Zander, DS | 1 |
| Cicale, MJ | 1 |
| Mergo, P | 1 |
| Van Cutsem, J | 1 |
| Van Gerven, F | 1 |
| Fransen, J | 1 |
| Janssen, PA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Intravenous Multiple Dose, Multi-Center Study to Investigate the Pharmacokinetics, Safety and Toleration of Voriconazole in Children Aged 2-12 Years Who Require Treatment for the Prevention of Systemic Fungal Infection[NCT00005912] | Phase 1 | 48 participants | Interventional | 2000-06-30 | Completed | ||
| A Phase II Trial to Evaluate the Safety and Tolerability of Nebulised Amphotericin B Lipid Complex (ABELCET®) in the Prophylaxis of Invasive Pulmonary Aspergillosis During Prolonged Neutropenia in Paediatric Patients With Acute Leukaemia[NCT01615809] | Phase 2 | 32 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia[NCT00001790] | Phase 1 | 120 participants | Interventional | 1998-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The incidence of invasive pulmonary aspergillosis during the Abelcet® prophylactic treatment period was assessed by the relation between the number of patients with invasive pulmonary aspergillosis and the number of paediatric patients on prophylaxis with Acute Leukaemia (AL) undergoing intensive chemotherapy. (NCT01615809)
Timeframe: at the Baseline visit (week 1) and at the end of the profilaxis treatment phase, up to 6 weeks
| Intervention | participants (Number) |
|---|---|
| Amphotericin B (ABELCET®) | 3 |
Percentage of deaths related to Invasive Pulmonary Aspergillosis during the prophylactic treatment period with Abelcet® in paediatric patients with Acute Leukaemia undergoing intensive chemotherapy. (NCT01615809)
Timeframe: at the Baseline visit (week 1) and at the end of the profilaxis treatment phase, up to 6 weeks
| Intervention | percentage of deaths (Number) |
|---|---|
| Amphotericin B (ABELCET®) | 0 |
is assessed by the proportion of patients who discontinue prophylactic treatment with Abelcet® due to an adverse event that is related or not to the study drug or for intolerability to it. The last week of treatment will have a different calendar for each participant, depending on the number of cicles needed by each patient (it has been anticipated up to 5 cicles of 2-6 weeks each). (NCT01615809)
Timeframe: at the Baseline visit (week 1) and during the Last week of treatment, up to 6 weeks
| Intervention | participants (Number) |
|---|---|
| Amphotericin B (ABELCET®) | 0 |
5 reviews available for fluconazole and Mucorales Infection
| Article | Year |
|---|---|
Treatment of invasive infections due to rare or emerging yeasts and moulds.
Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Clinical Trials as Topic; Dr | 2006 |
Invasive fungal infections in children: recent advances in diagnosis and treatment.
Topics: Amphotericin B; Aspergillosis; Candidiasis; Child; Coccidioidomycosis; Cytokines; Diagnosis, Differe | 1996 |
Invasive fungal infections in children: recent advances in diagnosis and treatment.
Topics: Amphotericin B; Aspergillosis; Candidiasis; Child; Coccidioidomycosis; Cytokines; Diagnosis, Differe | 1996 |
Invasive fungal infections in children: recent advances in diagnosis and treatment.
Topics: Amphotericin B; Aspergillosis; Candidiasis; Child; Coccidioidomycosis; Cytokines; Diagnosis, Differe | 1996 |
Invasive fungal infections in children: recent advances in diagnosis and treatment.
Topics: Amphotericin B; Aspergillosis; Candidiasis; Child; Coccidioidomycosis; Cytokines; Diagnosis, Differe | 1996 |
Invasive fungal infections in children: recent advances in diagnosis and treatment.
Topics: Amphotericin B; Aspergillosis; Candidiasis; Child; Coccidioidomycosis; Cytokines; Diagnosis, Differe | 1996 |
Invasive fungal infections in children: recent advances in diagnosis and treatment.
Topics: Amphotericin B; Aspergillosis; Candidiasis; Child; Coccidioidomycosis; Cytokines; Diagnosis, Differe | 1996 |
Invasive fungal infections in children: recent advances in diagnosis and treatment.
Topics: Amphotericin B; Aspergillosis; Candidiasis; Child; Coccidioidomycosis; Cytokines; Diagnosis, Differe | 1996 |
Invasive fungal infections in children: recent advances in diagnosis and treatment.
Topics: Amphotericin B; Aspergillosis; Candidiasis; Child; Coccidioidomycosis; Cytokines; Diagnosis, Differe | 1996 |
Invasive fungal infections in children: recent advances in diagnosis and treatment.
Topics: Amphotericin B; Aspergillosis; Candidiasis; Child; Coccidioidomycosis; Cytokines; Diagnosis, Differe | 1996 |
Opportunistic fungal infections: filamentous fungi and cryptococcosis.
Topics: Aged; Amphotericin B; Antifungal Agents; Aspergillosis; Cryptococcosis; Fluconazole; Humans; Middle | 1997 |
[New aspects of infections caused by Aspergillus and Mucor and other filamentous fungi in immunosuppressed patients].
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Aspergillosis; Bone Marrow | 1995 |
[Prevention and treatment of invasive mycoses in patients with neutropenia and bone marrow transplantation].
Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Bone Marrow Transplantation; Candidiasis; Candidia | 1995 |
29 other studies available for fluconazole and Mucorales Infection
| Article | Year |
|---|---|
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
Topics: Amphotericin B; Antifungal Agents; Caspofungin; Echinocandins; Fluconazole; Flucytosine; Humans; In | 2007 |
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
Topics: Amphotericin B; Animals; Antifungal Agents; Brain; Kidney; Male; Mice; Mucormycosis; Rhizopus; Triaz | 2009 |
Novel 2-aryl-4-aryloxyquinoline-based fungistatics for Mucor circinelloides. Biological evaluation of activity, QSAR and docking study.
Topics: Fluconazole; Humans; Mucor; Mucormycosis; Quantitative Structure-Activity Relationship; Quinolines | 2022 |
Recognizing mucormycosis in an immunocompromised patient.
Topics: Adult; Amphotericin B; Antifungal Agents; Debridement; Dexamethasone; Diagnosis, Differential; Fluco | 2020 |
Clinical Analysis of Diabetic Combined Pulmonary Mucormycosis.
Topics: Adult; Amphotericin B; Antifungal Agents; Diabetes Complications; Diabetes Mellitus; Female; Flucona | 2017 |
Molecular Confirmation of the Linkage between the
Topics: Antifungal Agents; Aspergillus fumigatus; Drug Resistance, Fungal; Fluconazole; Fungal Proteins; Gen | 2018 |
Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole.
Topics: Adult; Aged; Antifungal Agents; Aspergillosis; Dried Blood Spot Testing; Drug Monitoring; Fluconazol | 2013 |
Effect of Preexposure to Triazoles on Susceptibility and Virulence of Rhizopus oryzae.
Topics: Agar; Animals; Antifungal Agents; Culture Media; Disease Models, Animal; Drosophila melanogaster; Fe | 2015 |
Bilateral Rhizopus keratitis in a cocaine user.
Topics: Adult; Amphotericin B; Antifungal Agents; Cocaine-Related Disorders; Corneal Stroma; Corneal Ulcer; | 2016 |
[A case of rhinofacial entomophthoromycosis in Soudano-Sahelian tropical climate in Burkina Faso].
Topics: Aged; Burkina Faso; Conidiobolus; Facial Dermatoses; Female; Fluconazole; Humans; Mucormycosis; Nose | 2017 |
Cardiac mucormycosis with T-cell immunodeficiency.
Topics: Amphotericin B; Antifungal Agents; Female; Fluconazole; Humans; Immunologic Deficiency Syndromes; In | 2009 |
Breakthrough rhinocerebral mucormycosis in a liver transplant patient receiving caspofungin.
Topics: Adult; Antifungal Agents; Caspofungin; Echinocandins; Fatal Outcome; Female; Fluconazole; Hepatitis; | 2009 |
Successful treatment of peritonitis by C. bertholletiae in a chronic kidney failure patient on continuous ambulatory peritoneal dialysis after kidney rejection.
Topics: Antifungal Agents; Cunninghamella; Drug Administration Routes; Fluconazole; Follow-Up Studies; Graft | 2012 |
Successful treatment of mucormycosis peritonitis with liposomal amphotericin B in a patient on long-term peritoneal dialysis.
Topics: Abdominal Abscess; Amphotericin B; Antifungal Agents; Bacteroides fragilis; Combined Modality Therap | 2003 |
Mucormycoses in patients with hematologic malignancies: an emerging fungal infection.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Antineoplastic Agents; Communicable Diseases, Emergi | 2005 |
A case of rhinocerebral zygomycosis caused by Rhizopus arrhizus.
Topics: Aged; Antifungal Agents; Brain Infarction; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Edema; | 2006 |
Zygomycosis in the immunocompromised patient: a case report.
Topics: Absidia; Acute Disease; Aerosols; Amphotericin B; Amsacrine; Antibiotic Prophylaxis; Antifungal Agen | 2006 |
Successful treatment and limb salvage of mucor necrotizing fasciitis after kidney transplantation with posaconazole.
Topics: Alcaligenes; Amphotericin B; Amputation, Surgical; Antifungal Agents; Cefazolin; Combined Modality T | 2007 |
Palatal zygomycosis: experience of 21 cases.
Topics: Absidia; Adolescent; Adult; Aged; Amphotericin B; Antifungal Agents; Brain Diseases; Child; Diabetic | 2008 |
Fluconazole in the treatment of three cases of mucormycosis.
Topics: Adult; Anemia, Aplastic; Antifungal Agents; Diabetes Complications; Diabetes Mellitus, Type 2; Femal | 1995 |
Zosteriform zygomycosis.
Topics: Adult; Amphotericin B; Dermatomycoses; Diagnosis, Differential; Female; Fluconazole; Herpes Zoster; | 1995 |
[Peritoneal mucormycosis and fluconazole].
Topics: Aged; Female; Fluconazole; Humans; Mucormycosis; Peritonitis | 1993 |
Effects of systemic fluconazole therapy on in vitro adhesion of Candida albicans to buccal epithelial cells and changes of the cell surface proteins of the epithelial cells.
Topics: Adult; Antifungal Agents; Candida albicans; Candidiasis, Oral; Epithelium; Female; Fluconazole; Huma | 1996 |
Systemic antifungal drugs.
Topics: Amphotericin B; Anorexia; Antifungal Agents; Aspergillosis; Blastomycosis; Candidiasis; Coccidioidom | 1997 |
Apophysomyces elegans limb infection with a favorable outcome: case report and review.
Topics: Adult; Amphotericin B; Antifungal Agents; Dermatomycoses; Drug Therapy, Combination; Fluconazole; Hu | 1997 |
[A case of rhinocerebral mucormycosis presenting orbital apex syndrome].
Topics: Amphotericin B; Antifungal Agents; Combined Modality Therapy; Craniotomy; Diagnosis, Differential; F | 1998 |
Combination antifungal therapy in treatment of murine pulmonary mucormycosis: roles of quinolones and azoles.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Antifungal Agents; Disease Models, Animal; Drug Therap | 2000 |
Durable cure of mucormycosis involving allograft and native lungs.
Topics: Adult; Amphotericin B; Antifungal Agents; Drug Administration Routes; Drug Therapy, Combination; Fem | 2000 |
Treatment of experimental zygomycosis in guinea pigs with azoles and with amphotericin B.
Topics: Amphotericin B; Animals; Antifungal Agents; Azoles; Fluconazole; Guinea Pigs; Itraconazole; Ketocona | 1989 |